Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.8552W HIGH $19.17
Volume
258.63 K
Value Traded
1.79 M
Short % Float
22.82%
-6.21%Week
-25.91%1 Month
-4.9%3 Month
-7.16%6 Month
-8.71%5 Year
-8.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
986.03 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
712.72 M
Total Shares
53.53 M
Float Shares
13.80 M
Insiders
74.22%
Institutions
31.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SPTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Seaport Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Seaport Therapeutics, Inc.
31Total events
11Upcoming
12Tier-1 (high impact)
2026 to 2028Coverage
Upcoming catalysts 2
Event history 15
▲Topline ReadoutGlyphAlloClinical Data
Positive topline results from Phase 1 Driving Simulation Trial of GlyphAllo in healthy volunteers
healthy volunteers (driving impairment)source ↗
▲Primary Endpoint MetGlyphAlloClinical Data
Primary endpoint met: evening dosing of GlyphAllo 375 mg did not impair next-morning driving vs placebo on Day 5
healthy volunteers (driving impairment)source ↗
▲Secondary Endpoint DataGlyphAlloClinical Data
Key secondary endpoint met: single evening dose of GlyphAllo 250 mg did not impair next-morning driving vs placebo on Day 2
healthy volunteers (driving impairment)source ↗
▲Safety Data UpdateGlyphAlloClinical Data
GlyphAllo well-tolerated at all doses with no serious adverse events reported
healthy volunteers (driving impairment)source ↗
◆Enrollment CompleteGlyphAlloTrial
Enrollment in Phase 2b BUOY-1 trial on track
major depressive disordersource ↗
●Enrollment UpdateGlyphAlloTrial
Enrollment on track in Phase 2b BUOY-1 trial
major depressive disordersource ↗
◆Topline ReadoutGlyphAlloClinical Data
Topline data expected from driving simulation trial
healthy volunteerssource ↗
●Trial InitiationGlyphAgoTrial
Plans to initiate Phase 2a proof-of-pharmacology trial
generalized anxiety disorder with sleep disturbancesource ↗
▲Topline ReadoutGlyphAgoClinical Data
Positive topline results from MAD portion
healthy volunteerssource ↗
●Oral PresentationGlyphAlloPresentation
Presented overview of GlyphAllo development program at ASCP Annual Meeting
major depressive disordersource ↗
●Poster PresentationGlyphAlloPresentation
Poster presentation at ASCP Annual Meeting
major depressive disordersource ↗
▲Topline ReadoutGlyphAgoClinical Data
Positive topline results from head-to-head crossover and SAD portions
healthy volunteerssource ↗
Past FDA Catalysts and PDUFA Decisions
How SPTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$102M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 60%
Micro Cap(rank 393 of 655)
Percentile Rank
Seaport Therapeutics, Inc. faces pipeline headwinds (33/100), with $256M risk-adjusted pipeline value, led by SPT-300 in Major Depressive Disorder (MDD) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPT-300 Small moleculeNCT07161700 | Major Depressive Disorder (MDD) | Phase 2 | ENROLLING BY_INVITATION | 720 | May 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every SPTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GlyphAllo | driving performance | Phase 1 | 2026-09-09 | 375 mg did not impair next-morning driving performance compared to placebo on Day 5; 250 mg did not impair next-morning driving performance compared to placebo on Day 2Read More | Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy VolunteersRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HOMBACH ROBERT J.Director | Buy | 13,000 13,000 held | $18.14 | 06/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SPTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SPTX for Q2 2026. | ||||
SPTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SPTX ranks across every disease it competes in
Competitive Position is a premium feature
See how SPTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSPTX News
SPTX▲ +5.8%on this news
Seaport Therapeutics to Participate in September Investor Conferences
Seaport Therapeutics, a clinical-stage company focused on neuropsychiatric medicines, announced its participation in several investor conferences in September. The events will include a presentation and panel discussion led by CEO Daphne Zohar at the Goldman Sachs Life Sciences Symposium. This engagement aims to enhance investor relations and showcase the company's developments.
Read more →SPTX▼ -9.6%on this newsshared move
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Seaport Therapeutics has announced positive topline results from its Phase 1 driving simulation trial of GlyphAllo™. The trial, conducted with healthy volunteers, indicates the potential safety and efficacy of the product. This development marks a significant step forward for Seaport Therapeutics in their research efforts.
Read more →SPTXSeaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
Seaport Therapeutics has announced its participation in two significant events: Citi's 2026 Biopharma Back to School Conference and the 21st Annual Wells Fargo Healthcare Conference. These presentations are expected to provide insights into the company's developments and foster investor relations. The participation reflects the company's commitment to engaging with the biopharma community.
Read more →SPTXSeaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics has announced its financial results for the second quarter of 2026, showcasing notable corporate and clinical advancements. The report emphasizes the company's ongoing progress in its initiatives, reflecting a positive outlook for future developments.
Read more →SPTXUnlocking Medicines for Neuropsychiatry by Enhancing Oral Absorption Using a Lymphatic-targeting Prodrug Technology
The article discusses a new technology aimed at enhancing oral absorption of medications for neuropsychiatry. This lymphatic-targeting prodrug technology could potentially unlock new treatment options in the field. The focus on improving drug efficacy represents a significant advancement in pharmaceutical research.
Read more →SPTXPrediction of Human Pharmacokinetic Profiles of Glyph Platform Prodrugs Using Animal and Human Data via a Semi-mechanistic Pharmacokinetic Model
The article discusses a study on predicting human pharmacokinetic profiles of Glyph platform prodrugs. It utilizes both animal and human data through a semi-mechanistic pharmacokinetic model. This research aims to enhance the understanding of drug behavior in humans based on prior animal studies.
Read more →SPTX▲ +9%on this news
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics, a company founded by PureTech, has announced positive results from its Phase 1 proof-of-concept trial of GlyphAgo™. The trial involved healthy volunteers and demonstrated encouraging data regarding the drug's safety and efficacy. These findings suggest potential for further development in the therapeutic landscape.
Read more →SPTXSeaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics reported its Q1 2026 financial results, highlighting advancements in its clinical programs for neuropsychiatric disorders. The company is actively enrolling patients in the Phase 2b BUOY-1 trial for GlyphAllo, with topline data expected in early 2027. Additionally, new data from the GlyphAgo program indicate promising safety and efficacy profiles. The recent IPO raised $260 million to support ongoing development.
Read more →SPTXSeaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics has announced positive results from a Phase 1 proof-of-concept trial for GlyphAgo™, demonstrating its safety and tolerability in healthy volunteers. The multiple-ascending dose data supports further development of the therapy. This marks a significant milestone for the company in advancing GlyphAgo™.
Read more →SPTX▼ -5.8%on this news
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
Seaport Therapeutics, a clinical-stage company, announced its participation in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference and the UBS Virtual CNS Day. Management will engage in fireside chats and one-on-one meetings, showcasing their commitment to investor relations. The company focuses on developing novel treatments for neuropsychiatric disorders.
Read more →SPTX▼ -6.5%on this news
GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers
GlyphAllo, an orally bioavailable prodrug of allopregnanolone, has shown an EEG profile indicative of GABAA positive allosteric modulation in healthy volunteers. This suggests potential therapeutic benefits in modulating GABAA receptors. The study results may pave the way for further exploration in clinical applications.
Read more →SPTXSeaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Seaport Therapeutics has announced the pricing of its upsized initial public offering, offering 14,160,000 shares at $18.00 each, totaling approximately $254.9 million. The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026. The offering is expected to close on May 4, 2026, pending customary conditions.
Read more →SPTXSeaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Seaport Therapeutics has appointed Dr. Sharon Mates, the founder and former CEO of Intra-Cellular Therapies, to its Board of Directors. Dr. Mates has a strong background in neuropsychiatry and played a key role in the commercialization of the antipsychotic CAPLYTA. Her expertise is expected to enhance Seaport's mission to develop innovative treatments for neuropsychiatric disorders.
Read more →SPTXSeaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics announced positive topline results from its Phase 1 trial of GlyphAgo, a novel prodrug of agomelatine. The trial demonstrated a significant increase in bioavailability and reduced pharmacokinetic variability. GlyphAgo was well-tolerated, with no serious adverse effects reported, paving the way for further clinical trials in generalized anxiety disorder.
Read more →SPTXPredicted Liver Safety of GlyphAgo, a Lymphatic targeting Prodrug of Agomelatine That Avoids First-pass Metabolism
The article discusses GlyphAgo, a prodrug of Agomelatine designed to target lymphatics and enhance liver safety by avoiding first-pass metabolism. This innovative approach may lead to better therapeutic outcomes compared to traditional methods. The development of GlyphAgo is a significant advancement in drug formulation.
Read more →SPTXSeaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAllo (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
Seaport Therapeutics announced the publication of findings on GlyphAllo, a novel oral prodrug of allopregnanolone, in Science Translational Medicine. The study confirms its therapeutic potential in major depressive disorder (MDD) and supports the ongoing Phase 2b trial. GlyphAllo's unique formulation allows for enhanced bioavailability, making it a promising candidate for treating MDD.
Read more →SPTXAn oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
The article discusses a new oral allopregnanolone prodrug that successfully bypasses liver metabolism through lymphatic transport. This advancement significantly enhances bioavailability in both animal models and human subjects. The innovative approach may lead to improved therapeutic outcomes for patients requiring this treatment.
Read more →SPTXSeaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
Seaport Therapeutics has received up to $15 million from ARPA-H to advance GlyphCele, an oral prodrug targeting gut lymphatic dysfunction. This innovative therapy aims to address issues linked to metabolic diseases and pancreatic cancer by restoring lymphatic function. The collaboration with Monash Institute of Pharmaceutical Sciences enhances the potential impact of this research.
Read more →SPTXFrequency of Rater-based Efficacy Assessments Correlated with Magnitude of Placebo Response in Generalized Anxiety Disorder Trials
The article discusses a study on the correlation between the frequency of rater-based efficacy assessments and the magnitude of placebo responses in trials for Generalized Anxiety Disorder. The findings may provide insights into the design and interpretation of clinical trials in this area. Further details on the implications of these findings are not provided.
Read more →SPTXSeaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
Seaport Therapeutics presented a meta-analysis at the ISCTM Conference, revealing that clinician-administered assessments significantly influence placebo responses in generalized anxiety disorder trials. The study examined 22 trials and found no strong correlation with other design factors. This research builds on previous findings in major depressive disorder, emphasizing the need for optimized clinical trial designs to enhance drug development success.
Read more →About Seaport Therapeutics, Inc.
Headquarters6 TIDE STREET, BOSTON, MA, 02110
BIOPHARMAWATCH ELITE PLUS
Trade the next SPTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime